Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(24):1807; doi:10.1093/jnci/dji460
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Awards, Appointments, Announcements

{blacksquare} Steven A. Rosenberg, M.D., Ph.D., was honored with the inaugural Richard V. Smalley, M.D., Memorial Award.

Rosenberg is the chief of surgery at the National Cancer Institute and a professor of surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, D.C. Rosenberg received the award for his work in immunotherapy, gene therapy, and cell transfer therapy.

The award recognizes individuals who have displayed excellence in the field of therapeutic research with biological agents.

{blacksquare} Tyler E. Jacks, Ph.D., of the Massachusetts Institute of Technology and Howard Hughes Medical Institute (HHMI), Scott W. Lowe, Ph.D., of Cold Spring Harbor Laboratory and HHMI, and Jeff Wrana, Ph.D., of the University of Toronto and the Samuel Lunenfeld Research Institute, received the 2005 Paul Marks Prize for Cancer Research.

The prize recognizes substantial contributions to the basic understanding and treatment of cancer by scientists 45 years old and younger at the time of nomination. The three winners will share a $150,000 prize. Each finalist's research helped scientists understand the cellular mechanics behind tumor growth, proliferation, and response to treatment.

{blacksquare} Richard R. Matner, Ph.D., was appointed the director of technology transfer and commercial development at Roswell Park Cancer Institute in Buffalo, N.Y.

{blacksquare} Garth Powis, Ph.D., was appointed chair of the Department of Experimental Therapeutics and director of the Center for Targeted Therapy at the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer at the University of Texas M. D. Anderson Cancer Center in Houston.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?